Document Detail

Pharmacokinetics of teduglutide in subjects with renal impairment.
MedLine Citation:
PMID:  23187965     Owner:  NLM     Status:  Publisher    
PURPOSE: Teduglutide is a recombinant analogue of human glucagon-like peptide-2 that has recently been approved for the treatment of short bowel syndrome in adults. This study was designed to study the influence of renal function and age on teduglutide pharmacokinetics. METHODS: This was an open-label study with six parallel groups (6 subjects each). Three groups with renal impairment (moderate, severe and end-stage renal disease) were compared to healthy subjects with normal renal function, which were matched to the renal-impaired subjects with respect to demographics. At least two elderly subjects (≥65 years) were enrolled per group. A single dose of 10 mg teduglutide was subcutaneously administered to each subject. Teduglutide plasma concentrations were measured using a validated liquid chromatography method with tandem mass spectrometric detection, and the primary pharmacokinetic variables (AUC(inf) and C(max)) were calculated. RESULTS: Area under the concentration versus time curve extrapolated to infinity (AUC(inf)) and maximum plasma concentration (C(max)) of teduglutide in subjects with end-stage renal disease were approximately 2.59- and 2.08-fold higher, respectively, than those of healthy subjects. The AUC(inf) and C(max) were also slightly higher in subjects with moderate and severe renal impairment. Comparison of healthy subjects aged <65 years with healthy elderly subjects revealed very similar pharmacokinetics in both subgroups. CONCLUSIONS: In our study population, the primary pharmacokinetic parameters of teduglutide increased with increased severity of renal impairment. These results suggest that the daily dose of teduglutide should be reduced by 50 % in patients with moderate and severe renal impairment and end-stage disease. We found no effect of age on the pharmacokinetics of teduglutide in healthy subjects. The treatment was well tolerated, and there were no safety concerns.
Rüdiger Nave; Atef Halabi; Rolf Herzog; Peter Schaffer; Jörg Diefenbach; Stephan Krause; Peter Berghöfer; Gezim Lahu; Manfred Hartmann
Related Documents :
23428875 - Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant ...
24314975 - Evolution of quality of life in renal transplant recipients and patients with multiple ...
23684945 - Probability of deceased donor kidney transplantation based on % pra.
2805595 - Lithium clearance in chronic nephropathy.
19846395 - Renal phenotype of the cystinosis mouse model is dependent upon genetic background.
7040635 - Mechanisms involved in the renal responses to intravenous and renal artery infusions of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-28
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  -     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Nycomed GmbH, Nycomed: A Takeda Company, Constance, Germany,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Social stratification in the dissemination of statins after stroke in Sweden.
Next Document:  A systematic review of functional magnetic resonance imaging and diffusion tensor imaging modalities...